Download PDF
Digestive Disease Interventions 2019; 03(03): 193-202
DOI: 10.1055/s-0039-1694784
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA

Interventional Oncology for Hepatic Malignancy in Children

Kevin S. H. Koo
1   Section of Interventional Radiology, Department of Radiology, Seattle Children's Hospital, University of Washington, Seattle, Washington
,
Matthew P. Lungren
2   Section of Interventional Radiology, Department of Radiology, Lucile Packard Children's Hospital, Stanford University, Palo Alto, California
,
Allison Aguado
3   Division of Pediatric Radiology, Department of Medical Imaging, Nemours/Alfred I. duPont Hospital for Children, Wilmington, Delaware
› Author Affiliations
Further Information

Publication History

21 March 2019

13 June 2019

Publication Date:
27 August 2019 (online)

Also available at
    Permissions and Reprints

Abstract

The field of interventional radiology has become an integral contributor in the multidisciplinary oncological treatment of numerous solid tumors in the adult population, especially hepatic malignancies. With continued growth and sophistication in the field of pediatric interventional radiology, interventional oncology (IO) principles and techniques are increasingly applied to children. While primary pediatric hepatic malignancies are less frequent than in the adult population, application of these IO principles and modalities in adults is becoming more commonplace. This article reviews the increasing application of these IO principles and modalities for the treatment of primary pediatric hepatic malignancy, as well as their role in the multidisciplinary care of children afflicted with these diseases.

Keywords

interventional oncology - pediatric - hepatic malignancy
 

  • References

  • 1 Meyers RL. Tumors of the liver in children. Surg Oncol 2007; 16 (03) 195-203
    CrossrefPubMedGoogle Scholar
  • 2 Allan BJ, Wang B, Davis JS. , et al. A review of 218 pediatric cases of hepatocellular carcinoma. J Pediatr Surg 2014; 49 (01) 166-171 , discussion 171
    CrossrefPubMedGoogle Scholar
  • 3 Ismail H, Broniszczak D, Kaliciński P. , et al. Liver transplantation in children with hepatocellular carcinoma. Do Milan criteria apply to pediatric patients?. Pediatr Transplant 2009; 13 (06) 682-692
    CrossrefPubMedGoogle Scholar
  • 4 Lungren MP, Towbin AJ, Roebuck DJ. , et al. Role of interventional radiology in managing pediatric liver tumors : part 1: endovascular interventions. Pediatr Radiol 2018; 48 (04) 555-564
    CrossrefPubMedGoogle Scholar
  • 5 Aronson DC, Meyers RL. Malignant tumors of the liver in children. Semin Pediatr Surg 2016; 25 (05) 265-275
    CrossrefPubMedGoogle Scholar
  • 6 Czauderna P, Haeberle B, Hiyama E. , et al. The Children's Hepatic tumors International Collaboration (CHIC): novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. Eur J Cancer 2016; 52: 92-101
    CrossrefPubMedGoogle Scholar
  • 7 Czauderna P, Lopez-Terrada D, Hiyama E, Häberle B, Malogolowkin MH, Meyers RL. Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy. Curr Opin Pediatr 2014; 26 (01) 19-28
    CrossrefPubMedGoogle Scholar
  • 8 Wang J, Mao Y, Liu Y. , et al. Hepatocellular carcinoma in children and adolescents: clinical characteristics and treatment. J Gastrointest Surg 2017; 21 (07) 1128-1135
    CrossrefPubMedGoogle Scholar
  • 9 López-Terrada D, Alaggio R, de Dávila MT. , et al; Children's Oncology Group Liver Tumor Committee. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. Mod Pathol 2014; 27 (03) 472-491
    PubMedGoogle Scholar
  • 10 Murawski M, Weeda VB, Maibach R. , et al. Hepatocellular carcinoma in children: does modified platinum- and doxorubicin-based chemotherapy increase tumor RESECTABILITY and change outcome? Lessons learned from the SIOPEL 2 and 3 Studies. J Clin Oncol 2016; 34 (10) 1050-1056
    CrossrefPubMedGoogle Scholar
  • 11 Czauderna P, Mackinlay G, Perilongo G. , et al; Liver Tumors Study Group of the International Society of Pediatric Oncology. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol 2002; 20 (12) 2798-2804
    CrossrefPubMedGoogle Scholar
  • 12 Katzenstein HM, Krailo MD, Malogolowkin MH. , et al. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children's Cancer Group intergroup study. J Clin Oncol 2002; 20 (12) 2789-2797
    CrossrefPubMedGoogle Scholar
  • 13 Czauderna P. Adult type vs. childhood hepatocellular carcinoma--are they the same or different lesions? Biology, natural history, prognosis, and treatment. Med Pediatr Oncol 2002; 39 (05) 519-523
    CrossrefPubMedGoogle Scholar
  • 14 Towbin AJ, Meyers RL, Woodley H. , et al. 2017 PRETEXT: radiologic staging system for primary hepatic malignancies of childhood revised for the Paediatric Hepatic International Tumour Trial (PHITT). Pediatr Radiol 2018; 48 (04) 536-554
    CrossrefPubMedGoogle Scholar
  • 15 Meyers RL, Maibach R, Hiyama E. , et al. Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International Collaboration. Lancet Oncol 2017; 18 (01) 122-131
    CrossrefPubMedGoogle Scholar
  • 16 Schmid I, von Schweinitz D. Pediatric hepatocellular carcinoma: challenges and solutions. J Hepatocell Carcinoma 2017; 4: 15-21
    CrossrefPubMedGoogle Scholar
  • 17 Brown DB, Pilgram TK, Darcy MD. , et al. Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 2005; 16 (12) 1661-1666
    CrossrefPubMedGoogle Scholar
  • 18 Tsochatzis EA, Fatourou E, O'Beirne J, Meyer T, Burroughs AK. Transarterial chemoembolization and bland embolization for hepatocellular carcinoma. World J Gastroenterol 2014; 20 (12) 3069-3077
    CrossrefPubMedGoogle Scholar
  • 19 Tsochatzis E, Meyer T, Marelli L, Burroughs AK. Which transarterial therapy is best for hepatocellular carcinoma?--the evidence to date. J Hepatol 2010; 53 (03) 588
    CrossrefPubMedGoogle Scholar
  • 20 Maluccio MA, Covey AM, Porat LB. , et al. Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 2008; 19 (06) 862-869
    CrossrefPubMedGoogle Scholar
  • 21 Czauderna P, Zbrzezniak G, Narozanski W, Korzon M, Wyszomirska M, Stoba C. Preliminary experience with arterial chemoembolization for hepatoblastoma and hepatocellular carcinoma in children. Pediatr Blood Cancer 2006; 46 (07) 825-828
    CrossrefPubMedGoogle Scholar
  • 22 Lewandowski RJ, Mulcahy MF, Kulik LM. , et al. Chemoembolization for hepatocellular carcinoma: comprehensive imaging and survival analysis in a 172-patient cohort. Radiology 2010; 255 (03) 955-965
    CrossrefPubMedGoogle Scholar
  • 23 Dhand S, Gupta R. Hepatic transcatheter arterial chemoembolization complicated by postembolization syndrome. Semin Intervent Radiol 2011; 28 (02) 207-211
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Marelli L, Stigliano R, Triantos C. , et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 2007; 30 (01) 6-25
    CrossrefPubMedGoogle Scholar
  • 25 Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 1983; 148 (02) 397-401
    CrossrefPubMedGoogle Scholar
  • 26 Nakamura H, Hashimoto T, Oi H, Sawada S. Transcatheter oily chemoembolization of hepatocellular carcinoma. Radiology 1989; 170 (3 Pt 1): 783-786
    CrossrefPubMedGoogle Scholar
  • 27 Tsurusaki M, Murakami T. Surgical and locoregional therapy of HCC: TACE. Liver Cancer 2015; 4 (03) 165-175
    CrossrefPubMedGoogle Scholar
  • 28 Craig P, Young S, Golzarian J. Current trends in the treatment of hepatocellular carcinoma with transarterial embolization: variability in technical aspects. Cardiovasc Intervent Radiol 2019; 25 (01) 16
    PubMedGoogle Scholar
  • 29 Llovet JM, Real MI, Montaña X. , et al; Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359 (9319): 1734-1739
    CrossrefPubMedGoogle Scholar
  • 30 Lo CM, Ngan H, Tso WK. , et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35 (05) 1164-1171
    CrossrefPubMedGoogle Scholar
  • 31 Wong LL, Tanaka K, Lau L, Komura S. Pre-transplant treatment of hepatocellular carcinoma: assessment of tumor necrosis in explanted livers. Clin Transplant 2004; 18 (03) 227-234
    CrossrefPubMedGoogle Scholar
  • 32 Graziadei IW, Sandmueller H, Waldenberger P. , et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 2003; 9 (06) 557-563
    CrossrefPubMedGoogle Scholar
  • 33 Kamel IR, Bluemke DA, Ramsey D. , et al. Role of diffusion-weighted imaging in estimating tumor necrosis after chemoembolization of hepatocellular carcinoma. AJR Am J Roentgenol 2003; 181 (03) 708-710
    CrossrefPubMedGoogle Scholar
  • 34 Kim CJ, Kim HJ, Park JH. , et al. Radiologic response to transcatheter hepatic arterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma. Liver Int 2014; 34 (02) 305-312
    CrossrefPubMedGoogle Scholar
  • 35 Malagari K, Pomoni M, Kelekis A. , et al. Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33 (03) 541-551
    CrossrefPubMedGoogle Scholar
  • 36 Facciorusso A, Licinio R, Muscatiello N, Di Leo A, Barone M. Transarterial chemoembolization: evidences from the literature and applications in hepatocellular carcinoma patients. World J Hepatol 2015; 7 (16) 2009-2019
    CrossrefPubMedGoogle Scholar
  • 37 Gerber DA, Arcement C, Carr B, Towbin R, Mazariegos G, Reyes J. Use of intrahepatic chemotherapy to treat advanced pediatric hepatic malignancies. J Pediatr Gastroenterol Nutr 2000; 30 (02) 137-144
    CrossrefPubMedGoogle Scholar
  • 38 Arcement CM, Towbin RB, Meza MP. , et al. Intrahepatic chemoembolization in unresectable pediatric liver malignancies. Pediatr Radiol 2000; 30 (11) 779-785
    CrossrefPubMedGoogle Scholar
  • 39 Malogolowkin MH, Stanley P, Steele DA, Ortega JA. Feasibility and toxicity of chemoembolization for children with liver tumors. J Clin Oncol 2000; 18 (06) 1279-1284
    CrossrefPubMedGoogle Scholar
  • 40 Weiss KE, Sze DY, Rangaswami AA. , et al. Transarterial chemoembolization in children to treat unresectable hepatocellular carcinoma. Pediatr Transplant 2018; 22 (04) e13187
    CrossrefPubMedGoogle Scholar
  • 41 Andrews JC, Walker SC, Ackermann RJ, Cotton LA, Ensminger WD, Shapiro B. Hepatic radioembolization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994; 35 (10) 1637-1644
    PubMedGoogle Scholar
  • 42 Ho S, Lau WY, Leung TWT. , et al. Partition model for estimating radiation doses from yttrium-90 microspheres in treating hepatic tumours. Eur J Nucl Med 1996; 23 (08) 947-952
    CrossrefPubMedGoogle Scholar
  • 43 Lau WY, Leung WT, Ho S. , et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: a phase I and II study. Br J Cancer 1994; 70 (05) 994-999
    CrossrefPubMedGoogle Scholar
  • 44 Houle S, Yip TK, Shepherd FA. , et al. Hepatocellular carcinoma: pilot trial of treatment with Y-90 microspheres. Radiology 1989; 172 (03) 857-860
    CrossrefPubMedGoogle Scholar
  • 45 Blanchard RJ, Morrow IM, Sutherland JB. Treatment of liver tumors with yttrium-90 microspheres alone. Can Assoc Radiol J 1989; 40 (04) 206-210
    PubMedGoogle Scholar
  • 46 Shepherd FA, Rotstein LE, Houle S, Yip TCK, Paul K, Sniderman KW. A phase I dose escalation trial of yttrium-90 microspheres in the treatment of primary hepatocellular carcinoma. Cancer 1992; 70 (09) 2250-2254
    CrossrefPubMedGoogle Scholar
  • 47 Khan AS, Garcia-Aroz S, Ansari MA. , et al. Assessment and optimization of liver volume before major hepatic resection: current guidelines and a narrative review. Int J Surg 2018; 52: 74-81
    CrossrefPubMedGoogle Scholar
  • 48 Salem R, Mazzaferro V, Sangro B. Yttrium 90 radioembolization for the treatment of hepatocellular carcinoma: biological lessons, current challenges, and clinical perspectives. Hepatology 2013; 58 (06) 2188-2197
    CrossrefPubMedGoogle Scholar
  • 49 Salem R, Thurston KG. Radioembolization with 90Yttrium microspheres: a state-of-the-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol 2006; 17 (08) 1251-1278
    CrossrefPubMedGoogle Scholar
  • 50 Lewandowski RJ, Donahue L, Chokechanachaisakul A. , et al. (90) Y radiation lobectomy: outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes. J Surg Oncol 2016; 114 (01) 99-105
    CrossrefPubMedGoogle Scholar
  • 51 Hayashi S, Baba Y, Ueno K. , et al. Acceleration of primary liver tumor growth rate in embolized hepatic lobe after portal vein embolization. Acta Radiol 2007; 48 (07) 721-727
    CrossrefPubMedGoogle Scholar
  • 52 Hickey RM, Lewandowski RJ, Salem R. Yttrium-90 radioembolization for hepatocellular carcinoma. Semin Nucl Med 2016; 46 (02) 105-108
    CrossrefPubMedGoogle Scholar
  • 53 Emami B, Lyman J, Brown A. , et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 1991; 21 (01) 109-122
    PubMedGoogle Scholar
  • 54 Lawrence TS, Robertson JM, Anscher MS, Jirtle RL, Ensminger WD, Fajardo LF. Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995; 31 (05) 1237-1248
    CrossrefPubMedGoogle Scholar
  • 55 Kulik LM, Carr BI, Mulcahy MF. , et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 2008; 47 (01) 71-81
    CrossrefPubMedGoogle Scholar
  • 56 Salem R, Lewandowski RJ, Mulcahy MF. , et al. Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 2010; 138 (01) 52-64
    CrossrefPubMedGoogle Scholar
  • 57 Hilgard P, Hamami M, Fouly AE. , et al. Radioembolization with yttrium-90 glass microspheres in hepatocellular carcinoma: European experience on safety and long-term survival. Hepatology 2010; 52 (05) 1741-1749
    CrossrefPubMedGoogle Scholar
  • 58 Salem R, Lewandowski RJ, Kulik L. , et al. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma. Gastroenterology 2011; 140 (02) 497-507.e2
    CrossrefPubMedGoogle Scholar
  • 59 Salem R, Gilbertsen M, Butt Z. , et al. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol 2013; 11 (10) 1358-1365.e1
    CrossrefPubMedGoogle Scholar
  • 60 Kim PH, Choi SH, Kim J-H, Park SH. Comparison of radioembolization and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis of safety and efficacy. Korean J Radiol 2019; 20 (03) 385-398 0496
    CrossrefPubMedGoogle Scholar
  • 61 Christianson D, Rizzo D. . Provision of Karnofsky performance score (KPS) versus ECOG performance score (ECOG PS) to CIBMTR. January 2009 https://www.cibmtr.org/DataManagement/TrainingReference/Manuals/DataManagement/Documents/appendix-l.pdf . Accessed May 22, 2019
    PubMed
  • 62 Padia SA, Lewandowski RJ, Johnson GE. , et al; Society of Interventional Radiology Standards of Practice Committee. Radioembolization of hepatic malignancies: background, quality improvement guidelines, and future directions. J Vasc Interv Radiol 2017; 28 (01) 1-15
    CrossrefPubMedGoogle Scholar
  • 63 Hickey R, Mulcahy MF, Lewandowski RJ. , et al. Chemoradiation of hepatic malignancies: prospective, phase 1 study of full-dose capecitabine with escalating doses of yttrium-90 radioembolization. Int J Radiat Oncol Biol Phys 2014; 88 (05) 1025-1031
    CrossrefPubMedGoogle Scholar
  • 64 Iñarrairaegui M, Thurston KG, Bilbao JI. , et al. Radioembolization with use of yttrium-90 resin microspheres in patients with hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 2010; 21 (08) 1205-1212
    CrossrefPubMedGoogle Scholar
  • 65 Lewandowski RJ, Geschwind J-F, Liapi E, Salem R. Transcatheter intraarterial therapies: rationale and overview. Radiology 2011; 259 (03) 641-657
    CrossrefPubMedGoogle Scholar
  • 66 Ho S, Lau WY, Leung TWT, Chan M, Johnson PJ, Li AKC. Clinical evaluation of the partition model for estimating radiation doses from yttrium-90 microspheres in the treatment of hepatic cancer. Eur J Nucl Med 1997; 24 (03) 293-298
    PubMedGoogle Scholar
  • 67 BTG International Ltd. TheraSphere® Yttrium-90 Glass Microspheres. Package Insert. August 2016 :1–32. https://btgplc.com/BTG/media/TheraSphere-Documents/PDF/TheraSphere-Package-Insert_USA_Rev-14.pdf
    PubMed
  • 68 Sirtex Medical Limited. . SIR-Spheres® Y-90 Resin Microspheres. Package Insert. February 2017 :1–3. https://www.sirtex.com/us/clinicians/package-insert/
    PubMed
  • 69 Aguado A, Ristagno R, Towbin AJ. , et al. Transarterial radioembolization with yttrium-90 of unresectable primary hepatic malignancy in children. Pediatr Blood Cancer 2019; 66 (07) e27510
    CrossrefPubMedGoogle Scholar
  • 70 Thomas MB, Jaffe D, Choti MM. , et al. Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol 2010; 28 (25) 3994-4005
    CrossrefPubMedGoogle Scholar
  • 71 Benson III AB, Abrams TA, Ben-Josef E. , et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009; 7 (04) 350-391
    CrossrefPubMedGoogle Scholar
  • 72 Roebuck DJ. Paediatric interventional oncology. Cancer Imaging 2010; 10(1A): S27-S34
    CrossrefPubMedGoogle Scholar
  • 73 Hawkins CM, Kukreja K, Geller JI, Schatzman C, Ristagno R. Radioembolisation for treatment of pediatric hepatocellular carcinoma. Pediatr Radiol 2013; 43 (07) 876-881
    CrossrefPubMedGoogle Scholar
  • 74 Hong K, Georgiades C. Radiofrequency ablation: mechanism of action and devices. J Vasc Interv Radiol 2010; 21 (8, Suppl): S179-S186
    CrossrefPubMedGoogle Scholar
  • 75 Ahmed M, Liu Z, Humphries S, Goldberg SN. Computer modeling of the combined effects of perfusion, electrical conductivity, and thermal conductivity on tissue heating patterns in radiofrequency tumor ablation. Int J Hyperthermia 2008; 24 (07) 577-588
    CrossrefPubMedGoogle Scholar
  • 76 Hinshaw JL, Lubner MG, Ziemlewicz TJ, Lee Jr FT, Brace CL. Percutaneous tumor ablation tools: microwave, radiofrequency, or cryoablation--what should you use and why?. Radiographics 2014; 34 (05) 1344-1362
    CrossrefPubMedGoogle Scholar
  • 77 Seifert JK, Morris DL. World survey on the complications of hepatic and prostate cryotherapy. World J Surg 1999; 23 (02) 109-113 , discussion 113–114
    CrossrefPubMedGoogle Scholar
  • 78 Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer 2010; 116 (23) 5452-5460
    CrossrefPubMedGoogle Scholar
  • 79 Livraghi T, Goldberg SN, Lazzaroni S. , et al. Hepatocellular carcinoma: radio-frequency ablation of medium and large lesions. Radiology 2000; 214 (03) 761-768
    CrossrefPubMedGoogle Scholar
  • 80 Gervais DA, Goldberg SN, Brown DB, Soulen MC, Millward SF, Rajan DK. Society of Interventional Radiology position statement on percutaneous radiofrequency ablation for the treatment of liver tumors. J Vasc Interv Radiol 2009; 20 (7, Suppl): S342-S347
    CrossrefPubMedGoogle Scholar
  • 81 Xu HX, Xie XY, Lu MD. , et al. Ultrasound-guided percutaneous thermal ablation of hepatocellular carcinoma using microwave and radiofrequency ablation. Clin Radiol 2004; 59 (01) 53-61
    CrossrefPubMedGoogle Scholar
  • 82 Zhang NN, Lu W, Cheng XJ, Liu JY, Zhou YH, Li F. High-powered microwave ablation of larger hepatocellular carcinoma: evaluation of recurrence rate and factors related to recurrence. Clin Radiol 2015; 70 (11) 1237-1243
    CrossrefPubMedGoogle Scholar
  • 83 Wang C, Wang H, Yang W. , et al. Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma. Hepatology 2015; 61 (05) 1579-1590
    CrossrefPubMedGoogle Scholar
  • 84 Rong G, Bai W, Dong Z. , et al. Long-term outcomes of percutaneous cryoablation for patients with hepatocellular carcinoma within Milan criteria. PLOS One 2015; 10 (04) e0123065
    CrossrefPubMedGoogle Scholar
  • 85 van Laarhoven S, van Baren R, Tamminga RYJ, de Jong KP. Radiofrequency ablation in the treatment of liver tumors in children. J Pediatr Surg 2012; 47 (03) e7-e12
    PubMedGoogle Scholar
  • 86 Yevich S, Calandri M, Gravel G. , et al. Reiterative radiofrequency ablation in the management of pediatric patients with hepatoblastoma metastases to the lung, liver, or bone. Cardiovasc Intervent Radiol 2019; 42 (01) 41-47
    CrossrefPubMedGoogle Scholar
  • 87 Liu B, Zhou L, Huang G. , et al. First experience of ultrasound-guided percutaneous ablation for recurrent hepatoblastoma after liver resection in children. Sci Rep 2015; 5 (01) 16805
    CrossrefPubMedGoogle Scholar
  • 88 Chu KF, Dupuy DE. Thermal ablation of tumours: biological mechanisms and advances in therapy. Nat Rev Cancer 2014; 14 (03) 199-208
    CrossrefPubMedGoogle Scholar
  • 89 Sangro B, Gomez-Martin C, de la Mata M. , et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 2013; 59 (01) 81-88
    CrossrefPubMedGoogle Scholar
  • 90 Greten TF, Mauda-Havakuk M, Heinrich B, Korangy F, Wood BJ. Combined locoregional-immunotherapy for liver cancer. J Hepatol 2019; 70 (05) 999-1007
    CrossrefPubMedGoogle Scholar